What is the significance of Greg C. Garland's appointment to the Board?

Greg C. Garland's appointment brings significant executive leadership experience, particularly from his role as CEO of Phillips 66. His inclusion on the Audit Committee and Governance and Nominating Committee suggests a continued focus on financial oversight and corporate governance.

Why did Amgen amend its bylaws to designate a specific court for legal actions?

By designating the Delaware Court of Chancery as the exclusive forum, Amgen aims to consolidate legal proceedings related to certain types of corporate disputes in a court with specialized expertise in corporate law. This can lead to more consistent rulings, potentially reduce litigation costs, and provide greater predictability in legal outcomes.

How will Mr. Garland be compensated as a director?

Mr. Garland will receive a pro-rated annual retainer of $100,000 for the remainder of 2013, fees for committee meeting attendance, and a pro-rated grant of restricted stock units valued at $200,000 annually. He will also be reimbursed for expenses related to his director duties.

Are there any conflicts of interest with Mr. Garland's appointment?

The filing states that there are no transactions between Mr. Garland and Amgen that would require disclosure, nor are there any arrangements with other parties regarding his appointment, suggesting no immediate conflicts of interest.

AMGN 8-K: Leadership Changes & Corporate Changes

Summary

Amgen Inc. (AMGN) filed an 8-K on October 17, 2013, primarily to announce two significant corporate governance changes. The first, and most impactful for investors, is the appointment of Greg C. Garland, Chairman, President, and CEO of Phillips 66, to its Board of Directors, effective October 16, 2013. Mr. Garland brings extensive executive experience from the energy sector and will serve on the Audit Committee and the Governance and Nominating Committee. The second key development is an amendment to Amgen's Amended and Restated Bylaws, establishing the Court of Chancery of the State of Delaware as the sole and exclusive forum for a range of corporate legal actions, including derivative suits and claims related to fiduciary duties. This move aims to streamline litigation and potentially reduce legal costs associated with disputes governed by Delaware law.

Key Highlights

1Greg C. Garland, CEO of Phillips 66, appointed to Amgen's Board of Directors.
2Mr. Garland will serve on the Audit Committee and Governance and Nominating Committee.
3Amgen amended its Bylaws to designate the Delaware Court of Chancery as the exclusive forum for specific legal actions.
4The exclusive forum provision applies to derivative actions, breach of fiduciary duty claims, and actions under Delaware corporate law.
5This bylaw amendment is intended to centralize and potentially simplify litigation involving the company.
6Mr. Garland will receive pro-rated compensation and restricted stock units as a new director.
7The filing includes the press release announcing Mr. Garland's appointment as an exhibit.

AMGEN INC 8-K Report, Executive Changes (Oct 17, 2013)

Summary

Key Highlights

Frequently Asked Questions